Peter I Mackenzie

List of Publications by Year in Descending Order

153 papers	9,934 citations	51 h-index	97 g-index
153 ext. papers	10,652 ext. citations	4.8 avg, IF	5.94 L-index

#	Paper	IF	Citations
153	Use of a Baculovirus-Mammalian Cell Expression-System for Expression of Drug-Metabolizing Enzymes: Optimization of Infection With a Focus on Cytochrome P450 3A4.. *Frontiers in Pharmacology*, **2022**, 13, 832931	5.6	1
152	Regulation of human UDP-glycosyltransferase () genes by miRNAs.. *Drug Metabolism Reviews*, **2022**, 1-21	7	0
151	Circular RNAs of UDP-Glycosyltransferase () Genes Expand the Complexity and Diversity of the UGT Transcriptome. *Molecular Pharmacology*, **2021**, 99, 488-503	4.3	2
150	The Expression Profiles and Deregulation of UDP-Glycosyltransferase () Genes in Human Cancers and Their Association with Clinical Outcomes. *Cancers*, **2021**, 13,	6.6	3
149	The carboxyl-terminal di-lysine motif is essential for catalytic activity of UDP-glucuronosyltransferase 1A9. *Drug Metabolism and Pharmacokinetics*, **2020**, 35, 466-474	2.2	1
148	Hetero-oligomer formation of mouse UDP-glucuronosyltransferase (UGT) 2b1 and 1a1 results in the gain of glucuronidation activity towards morphine, an activity which is absent in homo-oligomers of either UGT. *Biochemical and Biophysical Research Communications*, **2020**, 525, 348-353	3.4	3
147	Potential Novel Role of UDP Glucuronosyltransferases 2B11 and 2B28 in Crosstalk Between Androgen and Lipid Signalling. *FASEB Journal*, **2020**, 34, 1-1	0.9	1
146	UDP-Glucuronosyltransferase (UGT)-mediated attenuations of cytochrome P450 3A4 activity: UGT isoform-dependent mechanism of suppression. *British Journal of Pharmacology*, **2020**, 177, 1077-1089	8.6	5
145	Coexpression of Human Hepatic Uridine Diphosphate Glucuronosyltransferase Proteins: Implications for Ontogenetic Mechanisms and Isoform Coregulation. *Journal of Clinical Pharmacology*, **2020**, 60, 722-733	2.9	3
144	The Expression Profiles of ADME Genes in Human Cancers and Their Associations with Clinical Outcomes. *Cancers*, **2020**, 12,	6.6	5
143	Investigation of the Endoplasmic Reticulum Localization of UDP-Glucuronosyltransferase 2B7 with Systematic Deletion Mutants. *Molecular Pharmacology*, **2019**, 95, 551-562	4.3	2
142	The UDP-Glycosyltransferase (UGT) Superfamily: New Members, New Functions, and Novel Paradigms. *Physiological Reviews*, **2019**, 99, 1153-1222	47.9	70
141	The UGTome: The expanding diversity of UDP glycosyltransferases and its impact on small molecule metabolism. *Pharmacology & Therapeutics*, **2019**, 204, 107414	13.9	14
140	Comprehensive characterization of mouse hepatic UDP-glucuronosyltransferases: Major participation of Ugt2b1 in bisphenol A glucuronidation. *FASEB Journal*, **2019**, 33, 508.10	0.9	
139	Deregulation of the Genes that Are Involved in Drug Absorption, Distribution, Metabolism, and Excretion in Hepatocellular Carcinoma. *Journal of Pharmacology and Experimental Therapeutics*, **2019**, 368, 363-381	4.7	26
138	Plasma extracellular nanovesicle (exosome)-derived biomarkers for drug metabolism pathways: a novel approach to characterize variability in drug exposure. *British Journal of Clinical Pharmacology*, **2019**, 85, 216-226	3.8	46
137	Drug and Chemical Glucosidation by Control Supersomes and Membranes from (Sf) 9 Cells: Implications for the Apparent Glucuronidation of Xenobiotics by UDP-glucuronosyltransferase 1A5. *Drug Metabolism and Disposition*, **2019**, 47, 271-278	4	1

136	Regulation of UDP-Glucuronosyltransferase 2B15 by miR-331-5p in Prostate Cancer Cells Involves Canonical and Noncanonical Target Sites. *Journal of Pharmacology and Experimental Therapeutics*, **2018**, 365, 48-59	4.7	7
135	Cooperative Regulation of Intestinal UDP-Glucuronosyltransferases 1A8, -1A9, and 1A10 by CDX2 and HNF4 Is Mediated by a Novel Composite Regulatory Element. *Molecular Pharmacology*, **2018**, 93, 541-552	4.3	6
134	Intergenic Splicing between Four Adjacent Genes () Gives Rise to Variant UGT Proteins That Inhibit Glucuronidation via Protein-Protein Interactions. *Molecular Pharmacology*, **2018**, 94, 938-952	4.3	6
133	Inhibition of human UDP-glucuronosyltransferase enzymes by lapatinib, pazopanib, regorafenib and sorafenib: Implications for hyperbilirubinemia. *Biochemical Pharmacology*, **2017**, 129, 85-95	6	51
132	Comprehensive Characterization of Mouse UDP-Glucuronosyltransferase (Ugt) Belonging to the Ugt2b Subfamily: Identification of Ugt2b36 as the Predominant Isoform Involved in Morphine Glucuronidation. *Journal of Pharmacology and Experimental Therapeutics*, **2017**, 361, 199-208	4.7	7
131	Regulation of UDP-Glucuronosyltransferases UGT2B4 and UGT2B7 by MicroRNAs in Liver Cancer Cells. *Journal of Pharmacology and Experimental Therapeutics*, **2017**, 361, 386-397	4.7	16
130	Exemestane and Its Active Metabolite 17-Hydroexemestane Induce UDP-Glucuronosyltransferase (UGT) 2B17 Expression in Breast Cancer Cells. *Journal of Pharmacology and Experimental Therapeutics*, **2017**, 361, 482-491	4.7	4
129	Advances in drug metabolism and pharmacogenetics research in Australia. *Pharmacological Research*, **2017**, 116, 7-19	10.2	8
128	Activation of ALDH1A1 in MDA-MB-468 breast cancer cells that over-express CYP2J2 protects against paclitaxel-dependent cell death mediated by reactive oxygen species. *Biochemical Pharmacology*, **2017**, 143, 79-89	6	18
127	Activation of the pro-migratory bone morphogenetic protein receptor 1B gene in human MDA-MB-468 triple-negative breast cancer cells that over-express CYP2J2. *International Journal of Biochemistry and Cell Biology*, **2016**, 80, 173-178	5.6	5
126	Genetic polymorphisms of human UDP-glucuronosyltransferase (UGT) genes and cancer risk. *Drug Metabolism Reviews*, **2016**, 48, 47-69	7	40
125	Novel Nine-Exon AR Transcripts (Exon 1/Exon 1b/Exons 2-8) in Normal and Cancerous Breast and Prostate Cells. *International Journal of Molecular Sciences*, **2016**, 18,	6.3	5
124	Introduction of an -Glycosylation Site into UDP-Glucuronosyltransferase 2B3 Alters Its Sensitivity to Cytochrome P450 3A1-Dependent Modulation. *Frontiers in Pharmacology*, **2016**, 7, 427	5.6	8
123	Androgen and Estrogen Receptors in Breast Cancer Coregulate Human UDP-Glucuronosyltransferases 2B15 and 2B17. *Cancer Research*, **2016**, 76, 5881-5893	10.1	37
122	Pro-migratory actions of the prostacyclin receptor in human breast cancer cells that over-express cyclooxygenase-2. *Biochemical Pharmacology*, **2015**, 96, 306-14	6	8
121	Regulation of Human UGT2B15 and UGT2B17 by miR-376c in Prostate Cancer Cell Lines. *Journal of Pharmacology and Experimental Therapeutics*, **2015**, 354, 417-25	4.7	34
120	Induction of human UDP-Glucuronosyltransferase 2B7 gene expression by cytotoxic anticancer drugs in liver cancer HepG2 cells. *Drug Metabolism and Disposition*, **2015**, 43, 660-8	4	21
119	Characterization of the comparative drug binding to intra- (liver fatty acid binding protein) and extra- (human serum albumin) cellular proteins. *Xenobiotica*, **2015**, 45, 847-57	2	5

118	Human UDP-Glucuronosyltransferases: Effects of altered expression in breast and pancreatic cancer cell lines. *Cancer Biology and Therapy*, **2015**, 16, 714-23	4.6	15
117	Suppression of Cytochrome P450 3A4 Function by UDP-Glucuronosyltransferase 2B7 through a Protein-Protein Interaction: Cooperative Roles of the Cytosolic Carboxyl-Terminal Domain and the Luminal Anchoring Region. *Molecular Pharmacology*, **2015**, 88, 800-12	4.3	17
116	The Nonspecific Binding of Tyrosine Kinase Inhibitors to Human Liver Microsomes. *Drug Metabolism and Disposition*, **2015**, 43, 1934-7	4	21
115	Induction of UDP-glucuronosyltransferase 2B15 gene expression by the major active metabolites of tamoxifen, 4-hydroxytamoxifen and endoxifen, in breast cancer cells. *Drug Metabolism and Disposition*, **2015**, 43, 889-97	4	10
114	A novel function for UDP glycosyltransferase 8: galactosidation of bile acids. *Molecular Pharmacology*, **2015**, 87, 442-50	4.3	38
113	Transporter-mediated uptake of UDP-glucuronic acid by human liver microsomes: assay conditions, kinetics, and inhibition. *Drug Metabolism and Disposition*, **2015**, 43, 147-53	4	14
112	Expression of androgen receptor splice variants in clinical breast cancers. *Oncotarget*, **2015**, 6, 44728-44	3.3	56
111	Insights into the UDP-sugar selectivities of human UDP-glycosyltransferases (UGT): a molecular modeling perspective. *Drug Metabolism Reviews*, **2015**, 47, 335-45	7	17
110	Identification of androgen receptor splice variant transcripts in breast cancer cell lines and human tissues. *Hormones and Cancer*, **2014**, 5, 61-71	5	48
109	Polymorphisms and haplotypes of the UDP-glucuronosyltransferase 2B7 gene promoter. *Drug Metabolism and Disposition*, **2014**, 42, 854-62	4	14
108	Epirubicin upregulates UDP glucuronosyltransferase 2B7 expression in liver cancer cells via the p53 pathway. *Molecular Pharmacology*, **2014**, 85, 887-97	4.3	33
107	Morphine glucuronidation and glucosidation represent complementary metabolic pathways that are both catalyzed by UDP-glucuronosyltransferase 2B7: kinetic, inhibition, and molecular modeling studies. *Journal of Pharmacology and Experimental Therapeutics*, **2014**, 349, 126-37	4.7	45
106	Transcriptional regulation of human UDP-glucuronosyltransferase genes. *Drug Metabolism Reviews*, **2014**, 46, 421-58	7	70
105	Alteration of the function of the UDP-glucuronosyltransferase 1A subfamily by cytochrome P450 3A4: different susceptibility for UGT isoforms and UGT1A1/7 variants. *Drug Metabolism and Disposition*, **2014**, 42, 229-38	4	28
104	The UDP-glucuronosyltransferases: their role in drug metabolism and detoxification. *International Journal of Biochemistry and Cell Biology*, **2013**, 45, 1121-32	5.6	422
103	The glycosidation of xenobiotics and endogenous compounds: versatility and redundancy in the UDP glycosyltransferase superfamily. *Pharmacology & Therapeutics*, **2012**, 134, 200-18	13.9	75
102	Inhibition of morphine glucuronidation in the liver microsomes of rats and humans by monoterpenoid alcohols. *Biological and Pharmaceutical Bulletin*, **2012**, 35, 1811-7	2.3	12
101	Effects of amino acid substitutions at positions 33 and 37 on UDP-glucuronosyltransferase 1A9 (UGT1A9) activity and substrate selectivity. *Biochemical Pharmacology*, **2012**, 84, 1511-21	6	20

100	Human UDP-glucuronosyltransferase expression in insect cells: ratio of active to inactive recombinant proteins and the effects of a C-terminal his-tag on glucuronidation kinetics. *Drug Metabolism and Disposition*, **2012**, 40, 1935-44	4	23
99	Identification of residues that confer sugar selectivity to UDP-glycosyltransferase 3A (UGT3A) enzymes. *Journal of Biological Chemistry*, **2012**, 287, 24122-30	5.4	23
98	Homodimerization of UDP-glucuronosyltransferase 2B7 (UGT2B7) and identification of a putative dimerization domain by protein homology modeling. *Biochemical Pharmacology*, **2011**, 82, 2016-23	6	23
97	Application of homology modeling to generate CYP1A1 mutants with enhanced activation of the cancer chemotherapeutic prodrug dacarbazine. *Molecular Pharmacology*, **2011**, 80, 879-88	4.3	13
96	The novel UDP glycosyltransferase 3A2: cloning, catalytic properties, and tissue distribution. *Molecular Pharmacology*, **2011**, 79, 472-8	4.3	56
95	A novel polymorphism in a forkhead box A1 (FOXA1) binding site of the human UDP glucuronosyltransferase 2B17 gene modulates promoter activity and is associated with altered levels of circulating androstane-3β,17β-diol glucuronide. *Molecular Pharmacology*, **2010**, 78, 714-22	4.3	29
94	Forkhead box protein A1 regulates UDP-glucuronosyltransferase 2B15 gene transcription in LNCaP prostate cancer cells. *Drug Metabolism and Disposition*, **2010**, 38, 2105-9	4	19
93	UGT3A: novel UDP-glycosyltransferases of the UGT superfamily. *Drug Metabolism Reviews*, **2010**, 42, 45-54	7	35
92	The regulation of UDP-glucuronosyltransferase genes by tissue-specific and ligand-activated transcription factors. *Drug Metabolism Reviews*, **2010**, 42, 99-109	7	51
91	The prediction of drug-glucuronidation parameters in humans: UDP-glucuronosyltransferase enzyme-selective substrate and inhibitor probes for reaction phenotyping and in vitro-in vivo extrapolation of drug clearance and drug-drug interaction potential. *Drug Metabolism Reviews*, **2010**, 42, 196-208	7	186
90	Effects of Andrographis paniculata and Orthosiphon stamineus extracts on the glucuronidation of 4-methylumbelliferone in human UGT isoforms. *Molecules*, **2010**, 15, 3578-92	4.8	9
89	The In Vitro Characterization of Inhibitory Drug–Drug Interactions Involving UDP-Glucuronosyltransferase **2010**, 217-236		8
88	Estrogen receptor alpha, fos-related antigen-2, and c-Jun coordinately regulate human UDP glucuronosyltransferase 2B15 and 2B17 expression in response to 17beta-estradiol in MCF-7 cells. *Molecular Pharmacology*, **2009**, 76, 425-39	4.3	40
87	Characterization of the binding of drugs to human intestinal fatty acid binding protein (IFABP): potential role of IFABP as an alternative to albumin for in vitro-in vivo extrapolation of drug kinetic parameters. *Drug Metabolism and Disposition*, **2009**, 37, 1395-403	4	30
86	Influence of N-terminal domain histidine and proline residues on the substrate selectivities of human UDP-glucuronosyltransferase 1A1, 1A6, 1A9, 2B7, and 2B10. *Drug Metabolism and Disposition*, **2009**, 37, 1948-55	4	48
85	Interaction of cytochrome P450 3A4 and UDP-glucuronosyltransferase 2B7: evidence for protein-protein association and possible involvement of CYP3A4 J-helix in the interaction. *Molecular Pharmacology*, **2009**, 75, 956-64	4.3	38
84	Identification of UDP glycosyltransferase 3A1 as a UDP N-acetylglucosaminyltransferase. *Journal of Biological Chemistry*, **2008**, 283, 36205-10	5.4	67
83	The "albumin effect" and in vitro-in vivo extrapolation: sequestration of long-chain unsaturated fatty acids enhances phenytoin hydroxylation by human liver microsomal and recombinant cytochrome P450 2C9. *Drug Metabolism and Disposition*, **2008**, 36, 870-7	4	66

82	Kinetic modeling of the interactions between 4-methylumbelliferone, 1-naphthol, and zidovudine glucuronidation by udp-glucuronosyltransferase 2B7 (UGT2B7) provides evidence for multiple substrate binding and effector sites. *Molecular Pharmacology*, **2008**, 74, 1152-62	4.3	50
81	Recent advances in the in silico modelling of UDP glucuronosyltransferase substrates. *Current Drug Metabolism*, **2008**, 9, 60-9	3.5	19
80	The configuration of the 17-hydroxy group variably influences the glucuronidation of beta-estradiol and epiestradiol by human UDP-glucuronosyltransferases. *Drug Metabolism and Disposition*, **2008**, 36, 2307-15	4	94
79	The "albumin effect" and drug glucuronidation: bovine serum albumin and fatty acid-free human serum albumin enhance the glucuronidation of UDP-glucuronosyltransferase (UGT) 1A9 substrates but not UGT1A1 and UGT1A6 activities. *Drug Metabolism and Disposition*, **2008**, 36, 1056-62	4	133
78	Carboxylic acid drug-induced DNA nicking in HEK293 cells expressing human UDP-glucuronosyltransferases: role of acyl glucuronide metabolites and glycation pathways. *Chemical Research in Toxicology*, **2007**, 20, 1520-7	4	15
77	Amino terminal domains of human UDP-glucuronosyltransferases (UGT) 2B7 and 2B15 associated with substrate selectivity and autoactivation. *Biochemical Pharmacology*, **2007**, 73, 1463-73	6	41
76	Binding of inhibitory fatty acids is responsible for the enhancement of UDP-glucuronosyltransferase 2B7 activity by albumin: implications for in vitro-in vivo extrapolation. *Journal of Pharmacology and Experimental Therapeutics*, **2007**, 321, 137-47	4.7	132
75	Isolation of the UDP-glucuronosyltransferase 1A3 and 1A4 proximal promoters and characterization of their dependence on the transcription factor hepatocyte nuclear factor 1alpha. *Drug Metabolism and Disposition*, **2007**, 35, 116-20	4	27
74	Critical roles of residues 36 and 40 in the phenol and tertiary amine aglycone substrate selectivities of UDP-glucuronosyltransferases 1A3 and 1A4. *Molecular Pharmacology*, **2007**, 72, 1054-62	4.3	48
73	Protein-protein interactions between rat hepatic cytochromes P450 (P450s) and UDP-glucuronosyltransferases (UGTs): evidence for the functionally active UGT in P450-UGT complex. *Drug Metabolism and Pharmacokinetics*, **2007**, 22, 367-76	2.2	36
72	Interactions with other human UDP-glucuronosyltransferases attenuate the consequences of the Y485D mutation on the activity and substrate affinity of UGT1A6. *Pharmacogenetics and Genomics*, **2007**, 17, 115-26	1.9	58
71	Hepatocyte nuclear factor1 transcription factors are essential for the UDP-glucuronosyltransferase 1A9 promoter response to hepatocyte nuclear factor 4alpha. *Pharmacogenetics and Genomics*, **2007** , 17, 25-36	1.9	27
70	Influence of mutations associated with Gilbert and Crigler-Najjar type II syndromes on the glucuronidation kinetics of bilirubin and other UDP-glucuronosyltransferase 1A substrates. *Pharmacogenetics and Genomics*, **2007**, 17, 1017-29	1.9	76
69	Inhibitory effects of adenine nucleotides and related substances on UDP-glucuronosyltransferase: structure-effect relationships and evidence for an allosteric mechanism. *Biochimica Et Biophysica Acta - General Subjects*, **2007**, 1770, 1557-66	4	15
68	In vitro-in vivo correlation for drugs and other compounds eliminated by glucuronidation in humans: pitfalls and promises. *Biochemical Pharmacology*, **2006**, 71, 1531-9	6	192
67	Inhibition of UDP-glucuronosyltransferase 2b7-catalyzed morphine glucuronidation by ketoconazole: dual mechanisms involving a novel noncompetitive mode. *Drug Metabolism and Disposition*, **2006**, 34, 1277-82	4	57
66	Sulfinpyrazone C-glucuronidation is catalyzed selectively by human UDP-glucuronosyltransferase 1A9. *Drug Metabolism and Disposition*, **2006**, 34, 1950-3	4	26
65	In vitro characterization of lamotrigine N2-glucuronidation and the lamotrigine-valproic acid interaction. *Drug Metabolism and Disposition*, **2006**, 34, 1055-62	4	173

64	Selectivity of substrate (trifluoperazine) and inhibitor (amitriptyline, androsterone, canrenoic acid, hecogenin, phenylbutazone, quinidine, quinine, and sulfinpyrazone) "probes" for human udp-glucuronosyltransferases. *Drug Metabolism and Disposition*, **2006**, 34, 449-56	4	203
63	Fatty acyl-CoA as an endogenous activator of UDP-glucuronosyltransferases. *Biochemical and Biophysical Research Communications*, **2006**, 345, 1649-56	3.4	12
62	Relationship between hyperbilirubinaemia and UDP-glucuronosyltransferase 1A1 (UGT1A1) polymorphism in adult HIV-infected Thai patients treated with indinavir. *Pharmacogenetics and Genomics*, **2006**, 16, 321-9	1.9	43
61	The caudal-related homeodomain protein Cdx2 and hepatocyte nuclear factor 1alpha cooperatively regulate the UDP-glucuronosyltransferase 2B7 gene promoter. *Pharmacogenetics and Genomics*, **2006**, 16, 527-36	1.9	19
60	Quantitative prediction of in vivo inhibitory interactions involving glucuronidated drugs from in vitro data: the effect of fluconazole on zidovudine glucuronidation. *British Journal of Clinical Pharmacology*, **2006**, 61, 427-39	3.8	138
59	Identification and characterization of functional hepatocyte nuclear factor 1-binding sites in UDP-glucuronosyltransferase genes. *Methods in Enzymology*, **2005**, 400, 22-46	1.7	14
58	Modulation of UDP-glucuronosyltransferase 2B7 function by cytochrome P450s in vitro: differential effects of CYP1A2, CYP2C9 and CYP3A4. *Biological and Pharmaceutical Bulletin*, **2005**, 28, 2026-7	2.3	32
57	S-Naproxen and desmethylnaproxen glucuronidation by human liver microsomes and recombinant human UDP-glucuronosyltransferases (UGT): role of UGT2B7 in the elimination of naproxen. *British Journal of Clinical Pharmacology*, **2005**, 60, 423-33	3.8	87
56	Human UDP-glucuronosyltransferase 1A5: identification, expression, and activity. *Journal of Pharmacology and Experimental Therapeutics*, **2005**, 315, 1143-9	4.7	56
55	Modulation of UDP-glucuronosyltransferase function by cytochrome P450: evidence for the alteration of UGT2B7-catalyzed glucuronidation of morphine by CYP3A4. *Molecular Pharmacology*, **2005**, 67, 665-72	4.3	60
54	Nomenclature update for the mammalian UDP glycosyltransferase (UGT) gene superfamily. *Pharmacogenetics and Genomics*, **2005**, 15, 677-85	1.9	640
53	Human udp-glucuronosyltransferases: isoform selectivity and kinetics of 4-methylumbelliferone and 1-naphthol glucuronidation, effects of organic solvents, and inhibition by diclofenac and probenecid. *Drug Metabolism and Disposition*, **2004**, 32, 413-23	4	296
52	Human PXR variants and their differential effects on the regulation of human UDP-glucuronosyltransferase gene expression. *Drug Metabolism and Disposition*, **2004**, 32, 340-7	4	135
51	Glucuronidation and the UDP-glucuronosyltransferases in health and disease. *Drug Metabolism and Disposition*, **2004**, 32, 281-90	4	209
50	Coordinate regulation of the human UDP-glucuronosyltransferase 1A8, 1A9, and 1A10 genes by hepatocyte nuclear factor 1alpha and the caudal-related homeodomain protein 2. *Molecular Pharmacology*, **2004**, 65, 953-63	4.3	63
49	Regulation of UDP glucuronosyltransferases in the gastrointestinal tract. *Toxicology and Applied Pharmacology*, **2004**, 199, 354-63	4.6	95
48	Predicting human drug glucuronidation parameters: application of in vitro and in silico modeling approaches. *Annual Review of Pharmacology and Toxicology*, **2004**, 44, 1-25	17.9	189
47	UGT1A10 is responsible for SN-38 glucuronidation and its expression in human lung cancers. *Anticancer Research*, **2004**, 24, 2893-6	2.3	37

46	Cloning and characterization of the human UDP-glucuronosyltransferase 1A8, 1A9, and 1A10 gene promoters: differential regulation through an interior-like region. *Journal of Biological Chemistry*, **2003**, 278, 36107-14	5.4	25
45	Isoform selectivity and kinetics of morphine 3- and 6-glucuronidation by human udp-glucuronosyltransferases: evidence for atypical glucuronidation kinetics by UGT2B7. *Drug Metabolism and Disposition*, **2003**, 31, 1086-9	4	175
44	Glucosidation of hyodeoxycholic acid by UDP-glucuronosyltransferase 2B7. *Biochemical Pharmacology*, **2003**, 65, 417-21	6	36
43	Genetic polymorphisms of UDP-glucuronosyltransferases and their functional significance. *Toxicology*, **2002**, 181-182, 453-6	4.4	150
42	Pharmacogenomics of human UDP-glucuronosyltransferases and irinotecan toxicity. *Molecular Pharmacology*, **2002**, 62, 446-50	4.3	97
41	The homeodomain Pbx2-Prep1 complex modulates hepatocyte nuclear factor 1alpha-mediated activation of the UDP-glucuronosyltransferase 2B17 gene. *Molecular Pharmacology*, **2002**, 62, 154-61	4.3	27
40	Tissue specific differences in the regulation of the UDP glucuronosyltransferase 2B17 gene promoter. *Pharmacogenetics and Genomics*, **2000**, 10, 809-20		29
39	Polymorphisms in UDP glucuronosyltransferase genes: functional consequences and clinical relevance. *Clinical Chemistry and Laboratory Medicine*, **2000**, 38, 889-92	5.9	81
38	4-hydroxyretinoic acid, a novel substrate for human liver microsomal UDP-glucuronosyltransferase(s) and recombinant UGT2B7. *Journal of Biological Chemistry*, **2000**, 275, 6908-14	5.4	91
37	Identification of uridine diphosphate glucuronosyltransferases involved in the metabolism and clearance of mycophenolic acid. *Therapeutic Drug Monitoring*, **2000**, 22, 10-3	3.2	68
36	Differential glucuronidation of bile acids, androgens and estrogens by human UGT1A3 and 2B7. *Journal of Steroid Biochemistry and Molecular Biology*, **1999**, 70, 101-8	5.1	120
35	Structural and functional studies of UDP-glucuronosyltransferases. *Drug Metabolism Reviews*, **1999**, 31, 817-99	7	417
34	Glucuronidation of Catechol Estrogens by Expressed Human UDP-Glucuronosyltransferases (UGTs) 1A1, 1A3, and 2B7. *Toxicological Sciences*, **1998**, 45, 52-57	4.4	69
33	Glucuronidation of catechol estrogens by expressed human UDP-glucuronosyltransferases (UGTs) 1A1, 1A3, and 2B7. *Toxicological Sciences*, **1998**, 45, 52-7	4.4	62
32	Characterization of two UDP glucuronosyltransferases that are predominantly expressed in human colon. *Biochemical and Biophysical Research Communications*, **1998**, 247, 704-9	3.4	96
31	UDP-glucuronosyltransferase, the role of the amino terminus in dimerization. *Journal of Biological Chemistry*, **1997**, 272, 26913-7	5.4	92
30	HNF1 alpha activates the rat UDP glucuronosyltransferase UGT2B1 gene promoter. *DNA and Cell Biology*, **1997**, 16, 207-14	3.6	23
29	The UDP glycosyltransferase gene superfamily: recommended nomenclature update based on evolutionary divergence. *Pharmacogenetics and Genomics*, **1997**, 7, 255-69		927

28	The regio- and stereo-selectivity of C19 and C21 hydroxysteroid glucuronidation by UGT2B7 and UGT2B11. *Archives of Biochemistry and Biophysics*, **1997**, 341, 207-11	4.1	63
27	The human UDP glucuronosyltransferase, UGT1A10, glucuronidates mycophenolic acid. *Biochemical and Biophysical Research Communications*, **1997**, 238, 775-8	3.4	59
26	Structure and function of uridine diphosphate glucuronosyltransferases. *Clinical and Experimental Pharmacology and Physiology*, **1997**, 24, 907-15	3	177
25	The role of glucuronidation in 7-ethyl-10-hydroxycamptothecin resistance in vitro. *Japanese Journal of Cancer Research*, **1997**, 88, 1211-7		42
24	UDP glucuronosyltransferase in the cirrhotic rat liver. *Journal of Gastroenterology and Hepatology (Australia)*, **1996**, 11, 373-9	4	19
23	Mutational analysis of the carboxy-terminal region of UDP-glucuronosyltransferase 2B1. *DNA and Cell Biology*, **1996**, 15, 489-94	3.6	30
22	Localization of uridine 5Sdiphosphate-glucuronosyltransferase in human liver injury. *Gastroenterology*, **1995**, 108, 1464-9	13.3	37
21	Bile acid glucuronidation by rat liver microsomes and cDNA-expressed UDP-glucuronosyltransferases. *BBA - Proteins and Proteomics*, **1994**, 1205, 75-82		14
20	Steroid UDP glucuronosyltransferases. *Journal of Steroid Biochemistry and Molecular Biology*, **1992**, 43, 1099-105	5.1	41
19	Isolation, sequence, and developmental expression of rat UGT2B2: the gene encoding a constitutive UDP glucuronosyltransferase that metabolizes etiocholanolone and androsterone. *DNA and Cell Biology*, **1991**, 10, 515-24	3.6	48
18	The UDP glucuronosyltransferase gene superfamily: suggested nomenclature based on evolutionary divergence. *DNA and Cell Biology*, **1991**, 10, 487-94	3.6	241
17	Drug glucuronidation in humans **1991**, 51, 347-69		282
16	Tolbutamide and phenytoin hydroxylations by cDNA-expressed human liver cytochrome P4502C9. *Biochemical and Biophysical Research Communications*, **1991**, 175, 1112-8	3.4	182
15	The effect of N-linked glycosylation on the substrate preferences of UDP glucuronosyltransferases. *Biochemical and Biophysical Research Communications*, **1990**, 166, 1293-9	3.4	23
14	Localization of UDP glucuronosyltransferase gene(s) on mouse chromosome 5. *Somatic Cell and Molecular Genetics*, **1987**, 13, 179-82		12
13	Separation of different UDP glucuronosyltransferase activities according to charge heterogeneity by chromatofocusing using mouse liver microsomes. Three major types of aglycones. *Biochemical Pharmacology*, **1985**, 34, 737-46	6	10
12	Effect of different detergent systems on the molecular size of UDP glucuronosyltransferase and other microsomal drug-metabolizing enzymes. *Membrane Biochemistry*, **1984**, 5, 193-207		11
11	Isolation and characterization of full-length mouse cDNA and genomic clones of 3-methylcholanthrene-inducible cytochrome P1-450 and P3-450. *Gene*, **1984**, 29, 281-92	3.8	76

10	Purification and immunochemical characterization of a low-pI form of UDP glucuronosyltransferase from mouse liver. *Archives of Biochemistry and Biophysics*, **1984**, 231, 487-97	4.1	47
9	Cell-free translation of mouse liver mRNA coding for two forms of UDP glucuronosyltransferase. *Archives of Biochemistry and Biophysics*, **1984**, 230, 676-80	4.1	18
8	Cleavage of nascent UDP glucuronosyltransferase from rat liver by dog pancreatic microsomes. *Biochemical and Biophysical Research Communications*, **1984**, 122, 1441-9	3.4	45
7	Differential induction and glycosylation of UDP-glucuronosyltransferase. *Biochemical Society Transactions*, **1984**, 12, 54-5	5.1	2
6	UDPglucosyltransferase and its kinetic fluorimetric assay. *FEBS Journal*, **1983**, 130, 141-5		7
5	Differences in UDP-glucuronosyltransferase activities in congenic inbred rats homozygous and heterozygous for the jaundice locus. *Biochemical Pharmacology*, **1983**, 32, 3777-81	6	34
4	Purification of a form of mouse liver UDP glucuronosyltransferase which glucuronidates androgens. *The Journal of Steroid Biochemistry*, **1983**, 19, 1097-102		9
3	Differential induction of UDP glucuronosyltransferase activities towards various substrates after polycyclic aromatic hydrocarbon administration to rats. *Toxicology Letters*, **1982**, 12, 259-63	4.4	8
2	A comparison of the isoelectric points of mouse liver UDP-glucuronosyltransferase enzymes conjugating the twelve benzo[a]pyrene phenols. *Biochemical and Biophysical Research Communications*, **1982**, 109, 1075-82	3.4	7
1	A sensitive kinetic assay for UDPglucuronosyltransferase using 1-naphthol as substrate. *Analytical Biochemistry*, **1980**, 109, 362-8	3.1	70